Forever Soldiers To Fight Forever Wars

by | Jul 13, 2021

2021 07 13 08 09

The U.S. military says it is months away from launching clinical trials of a pill designed to block or reduce many degenerative effects of aging—an oral treatment that a leading researcher in the field says is better than nothing while questioning how effective it will ultimately prove.

U.S. Special Operations Command (SOCOM)—which develops and employs Special Operations Forces worldwide to advance U.S. policies and objectives—has “completed preclinical safety and dosing studies in anticipation of follow-on performance testing” of a first-in-class nicotinamide adenine dinucleotide, oxidized state (NAD+) enhancer, a small molecule drug being developed by Metro International Biotech (MetroBiotech), Navy Cmdr. Timothy A. Hawkins, a spokesperson for SOCOM, told GEN.

SOCOM and MetroBiotech are set to start clinical trials during the 2022 federal fiscal year, which starts October 1.

“If the preclinical studies and clinical trials bear out, the resulting benefits include improved human performance, such as increased endurance and faster recovery from injury,” Hawkins said.

“This effort in particular is about enhancing the mission readiness of our forces by improving performance characteristics that typically decline with age,” Hawkins explained. “These efforts are not about creating physical traits that don’t already exist naturally.”

The SOCOM testing is among studies being carried out to assess MetroBiotech’s lead candidate, David J. Livingston, PhD, MetroBiotech’s president and CSO, told GEN.  “I can confirm that we and our clinical partners have completed multiple Phase I human safety trials of a lead molecule,” Livingston said. “Metro has also initiated exploratory Phase II studies in several areas of therapeutic application, including the treatment of rare diseases, diseases of aging, and in collaboration with SOCOM, studies on the effects of our compounds on muscle energetics and human performance.” Livingston said MetroBiotech won’t discuss details of its clinical trials in advance of future postings on or joint publications of clinical data.
Potential to “truly delay aging”

SOCOM has spent $2.8 million on its anti-aging effort since it began in 2018, Hawkins said.

Lisa R. Sanders, director of science and technology for Special Operations Forces, Acquisition, Technology, & Logistics, said during a virtual conference last month that SOCOM was able to fund its anti-aging testing through Other Transaction Authority (OTA) funds and Middle Tier Acquisition authority, created in 2015 to enable rapid acquisitions designed to deliver capabilities within 2–5 years.

“This small molecule has the potential, if it is successful, to truly delay aging [and] truly prevent onset of injury, which is just amazingly game-changing,” Sanders said, addressing “Assisting the Modern Warfighter,” a featured session held as part of the Defense One Defense Tech Summit, held June 21–25.

More here at Genetic And Engineering News

6 Libooks011721lg

Our Books

Shop books published by the Libertarian Institute.

Libertarian Institute Merch from Libertas Bella

Support via Amazon Smile

Related Articles


Daniel Hale: Drone Program Whistleblower

Daniel Hale has been sentenced to nearly four years of prison for documenting what other drone operators had spoken out about: that military-aged males killed by missiles launched by drones were assumed guilty until proven innocent. Under President Obama, thousands of...

read more

No Mandatory Vaccination!

George Mason University Professor Donald J. Boudreaux has written an article worthy of everyone's attention: "'Externality' Is No Good Excuse for Mandatory Vaccination." Some people think the case for mandatory vaccination is irrefutably made by simply saying that the...

read more

Pin It on Pinterest

Share This